The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-05 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
1 of the 20 Greatest WWE Wrestlers Of All Time Texas Wrestling Alliance TWA Tag Team Championship (1 time) – with Rod Price World Championship Wrestling WCW World Television Championship (2 times) WCW United States Heavyweight Championship (2 times) WCW World Tag Team Championship (1 time) – with Brian Pillman NWA World Tag Team Championship (1 time) – with Brian Pillman World Wrestling Federation/World Wrestling Entertainment/WWE WWF Championship (6 times) WWF Intercontinental Championship (2 times) WWF Tag Team Championship (4 times) – with Shawn Michaels (1), Dude Love (1), The Undertaker (1), and Triple H (1) Million Dollar Championship (1 time) King of the Ring (1996) Royal Rumble (1997, 1998, 2001) Undisputed WWF Championship #1 Contenders Tournament (2002) Fifth Triple Crown Champion Slammy Award (2 times) Freedom of Speech (1997) Best Original WWE Network Show – Stone Cold Podcast (2015) WWE Hall of Fame (2 times) Class of 2009 – individually Class of 2025 – Immortal Moment vs. Bret Hart at WrestleMania 13 Wrestling Observer Newsletter Best Box Office Draw (1998, 1999) Best Brawler (2001) Best Gimmick (1997, 1998) Best Heel (1996) Best on Interviews (1996–1998, 2001) Best Non-Wrestler (2003) Feud of the Year (1997) vs. The Hart Foundation Feud of the Year (1998, 1999) vs. Vince McMahon Match of the Year (1997) vs. Bret Hart in a submission match at WrestleMania 13 Most Charismatic (1997, 1998) Rookie of the Year (1990) Tag Team of the Year (1993) with Brian Pillman as The Hollywood Blonds Worst Worked Match of the Year (1991) with Terrance Taylor vs.
Criminals learn through associations with one another. The success of organized crime groups is therefore dependent upon the strength of their communication and the enforcement of their value systems, the recruitment and training processes employed to sustain, build or fill gaps in criminal operations. An understanding of this theory sees close associations between criminals, imitation of superiors, and understanding of value systems, processes and authority as the main drivers behind organized crime. Interpersonal relationships define the motivations the individual develops, with the effect of family or peer criminal activity being a strong predictor of inter-generational offending. This theory also developed to include the strengths and weaknesses of reinforcement, which in the context of continuing criminal enterprises may be used to help understand propensities for certain crimes or victims, level of integration into the mainstream culture and likelihood of recidivism / success in rehabilitation.
I am left with the impression that the attorneys in charge of the Labscam investigation ... seek to take far more credit for the overall success of the proceedings than is rightly due. Philadelphia-based SmithKline agreed to pay the government $325 million which is considered as one of the largest civil settlement ever in a whistle-blower lawsuit. The company settled after the government alleged it paid kickbacks to doctors, billed the government for laboratory tests not performed and committed other violations. SmithKline has denied the allegations, saying the violations were unintentional and the result of ambiguities in regulations and guidelines. When interest and payments to state Medicare funds were taken into account, the final settlement came to about $321 million. VanArtsdalen said Merena and the other whistle-blowers accounted for all but about $15 million of that total. The government failed to reach an agreement with litigants Merena and Grossenbacher on the amount that they would receive from the settlement agreement. The government maintained that Merena was entitled to approximately $10 million of the $65 million attributable to the non-"automated chemistry" claims and has paid Merena this amount. The government and the Spear relators have a proposed agreement that, if approved, will award the Spear relators 15% of the $13 million that the government attributed to a claim called the "CBC Indices" claim. The government previously agreed to pay the whistle-blowers a minimum of $9.7 million but only if they dropped claims to a larger portion.
Through this method, researchers can more effectively improve the functional properties of proteins to meet specific biotechnology or medical needs. Although this method has high requirements for information and technology and is relatively difficult to implement, with the development of computing technology and bioinformatics, the application prospects of semi-rational design in protein engineering are becoming more and more broad.
=== Regulation of cell adhesion, migration, and survival === The α1β1 Integrin receptor binds collagens in the ECM and connects the α1β1 integrin complex to f-actin through the cytoplasmic tails of the integrin's recruitment of focal adhesion adaptor proteins (Talin, Kindlin, Paxillin, Vinculin, A-Actinin) which connects ECM to the actin cytoskeleton inside cells. This helps cells stick to and move throughout tissues. The interactions Integrin Alpha-1 has with the extracellular matrix promotes cell adhesion, migration, survival, and metastasis. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1 promotes tumor cell adhesion and migration on collagen substrates. Loss of ITGA1 reduces collagen-dependent attachment, spreading, and cellular viability, demonstrating that ITGA1 functions as a receptor linking ECM composition to cellular behavior. ITGA1 also supports survival of aggressive tumor cell populations. In PDAC, ITGA1 identifies ALDH1-high stem-like cancer cells and contributes to the maintenance and viability of tumor-initiating populations. Reduction of ITGA1 decreases survival of ALDH1-high cells, which suggests that ITGA1 regulates pathways involved in tumor cell persistence and stem-like properties.
Sources: en.wikipedia.org
== Treatment == Antibiotic therapy to prevent streptococcal infection (prophylaxis). Steroids to suppress inflammation. Provide balanced diet in terms of calories, sodium and potassium. A low-protein diet is often recommended in chronic kidney disease, but benefits may be limited in case of glomerular disorders, the response in patients with chronic glomerulonephritis correlated closely with the effect of diet on proteinuria in these patients. Monitor for sign of kidney failure, heart failure, and hypertensive encephalopathy.
== History == Tanning hide into leather involves a process which permanently alters the protein structure of skin, making it more durable and less susceptible to decomposition and coloring. The place where hides are processed is known as a tannery.
Epithelial cells climb over one another in order to migrate. This growing sheet of epithelial cells is often called the epithelial tongue. The first cells to attach to the basement membrane form the stratum basale. These basal cells continue to migrate across the wound bed, and epithelial cells above them slide along as well. The more quickly this migration occurs, the less of a scar there will be. Fibrin, collagen, and fibronectin in the ECM may further signal cells to divide and migrate. Like fibroblasts, migrating keratinocytes use the fibronectin cross-linked with fibrin that was deposited in inflammation as an attachment site to crawl across.
=== Compilation albums === Mrs. Dolphin (10 January 1991), Japanese release containing Barging Into the Presence of God and the Half-Life EPs with the tracks "Colours and Shapes" and "A Deeper Sleep for Steven"
== Drug development cost == The costs spent on tecemotide development – beginning in the late 1990s – have not been published in detail by the companies Biomira/Oncothyreon, Merck KGaA, and Ono Pharmaceutical. Additionally, the estimation of the full cost of bringing a new drug to market – from discovery through clinical trials to approval – is complex and controversial. However, a cautious estimate of the tecmotide development cost spent until 2014 ranges from €300 to €500 million (US$390 to US$650 million; for more information see Drug development).
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.